Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria.

Gaya, Anna; Munir, Talha; Urbano-Ispizua, Alvaro; Griffin, Morag; Taubel, Jorg; Bush, Jim; Bhan, Ishir; Borodovsky, Anna; Wang, Yue; Badri, Prajakta; Garg, Pushkal

Gaya, Anna; Munir, Talha; Urbano-Ispizua, Alvaro; Griffin, Morag; Taubel, Jorg; Bush, Jim; Bhan, Ishir; Borodovsky, Anna; Wang, Yue; Badri, Prajakta; Garg, Pushkal.

Afiliação

Gaya A; Hospital Clinic of Barcelona Barcelona Spain.
Munir T; Leeds Teaching Hospitals St. James' University Hospital Leeds UK.
Urbano-Ispizua A; Hospital Clinic of Barcelona Barcelona Spain.
Griffin M; August Pi i Sunyer Biomedical Research Institute Barcelona Spain.
Taubel J; Leeds Teaching Hospitals St. James' University Hospital Leeds UK.
Bush J; Richmond Pharmacology, Ltd St. George's University of London London UK.
Bhan I; Labcorp Clinical Research Unit Springfield House, Hyde St Leeds UK.
Borodovsky A; Alnylam Pharmaceuticals Cambridge Massachusetts USA.
Wang Y; Alnylam Pharmaceuticals Cambridge Massachusetts USA.
Badri P; Alnylam Pharmaceuticals Cambridge Massachusetts USA.
Garg P; Alnylam Pharmaceuticals Cambridge Massachusetts USA.

EJHaem ; 4(3): 612-624, 2023 Aug.

Article em En | MEDLINE | ID: mdl-37601837

Palavras-chave

cemdisiran; complement C5; paroxysmal nocturnal hemoglobinuria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: EJHaem Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google